OncoMatch/Clinical Trials/NCT06484985
Study of AXT-1003 in Subjects With Advanced Malignant Tumors.
Is NCT06484985 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies AXT-1003 for non-hodgkin lymphoma.
Treatment: AXT-1003 — This is a Phase I study of AXT-1003 to assess the safety, tolerability, and pharmacokinetics in patients with advanced malignancies.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Tumor Agnostic
Disease stage
Required: Stage III, IV
locally advanced unresectable and metastatic solid tumors
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
adequate organ and bone marrow functions
Kidney function
adequate organ and bone marrow functions
Liver function
adequate organ and bone marrow functions
Adequate organ and bone marrow functions
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify